Plain English coverage of UK weight loss injections including Mounjaro, Wegovy and Ozempic — how they work, NHS access, private clinic costs and real patient experiences.
New real-world data presented at EASD suggests a small difference in major cardiovascular events between people who increased their Ozempic dose and those who switched to Mounjaro. But this wasn’t a randomised head-to-head trial, and the result needs careful interpretation.
Novo Nordisk says CagriSema produced more weight loss than tirzepatide in the Phase 3 REIMAGINE 5 trial. We explain what the result shows, why the 5 mg tirzepatide dose matters, and what it means for Mounjaro users in the UK.
EloraTZP is an investigational combination product that pairs tirzepatide — the active ingredient in Mounjaro — with a separate compound aimed at reducing gastrointestinal side effects. Developed by Elorac Pharma, it is currently in clinical trials and is not approved or available in the UK. Significant Phase 2 results are expected later in 2025, and this article will be updated when that data is published.
New trial results suggest retatrutide may produce greater average weight loss than tirzepatide, but the comparison is more complicated than the headlines imply. Here is what the evidence actually shows, why cross-trial numbers have real limits, and what it means for UK patients currently on Mounjaro.
New analysis suggests GLP-1 weight loss treatments including Mounjaro and Wegovy have reached three million UK adults, with consulting firm PwC forecasting that number could more than double to seven million as pill-based alternatives and new medicines approach availability. Worldpanel data cited by Grocery Gazette shows GLP-1 users now live in more than six in every hundred British households — and retailers are already redesigning their products in response.
A review published in the Journal of Clinical Investigation in September 2026 brings together growing evidence that GLP-1-targeted medicines may reduce alcohol consumption — and potentially affect other substance-use disorders. Controlled human trial data now exists, though researchers are clear it is early and limited. Here is what the evidence actually shows, and what it does not yet prove.
Both retatrutide and Mounjaro come from the same manufacturer, but they work differently and sit in very different places in terms of availability. Here is what UK readers need to know about how the two treatments compare — and why one of them cannot safely be accessed yet.
Medical professionals are raising concerns that retatrutide — a powerful triple-receptor weight-loss medicine still in clinical trials — is being sought by bodybuilders and fitness enthusiasts for body composition rather than obesity treatment. There is currently no MHRA-authorised retatrutide product available in the UK, meaning anything sold under that name cannot be reliably verified for safety, strength or contents. Here is what the warnings actually say, and what it means for people genuinely waiting for a licensed version.
Reports of serious liver toxicity linked to unverified products sold as retatrutide are circulating in patient communities right now. Eli Lilly has confirmed no licensed retatrutide exists outside its own clinical trials. If you have been following this medication's development, here is what the discussion looks like and what it means for you.
NHS dispensing of weight loss injections passed 4 million items in a single year. An estimated 3.3 million UK adults are set to use weight loss jabs in 2026. These numbers sound impressive — but they hide a more complicated picture that every patient considering treatment should understand.
We use cookies to understand how The Peptide Brief is used and to improve the site. You can accept analytics cookies, reject them, or manage your preferences.